As of 2025-12-18, the Intrinsic Value of Relmada Therapeutics Inc (RLMD) is -3.83 USD. This RLMD valuation is based on the model Peter Lynch Fair Value. With the current market price of 4.01 USD, the upside of Relmada Therapeutics Inc is -195.52%.
Based on its market price of 4.01 USD and our intrinsic valuation, Relmada Therapeutics Inc (RLMD) is overvalued by 195.52%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -3.83 - -3.83 | -3.83 | -195.52% |
| P/E | (8.33) - (12.18) | (11.45) | -385.6% |
| DDM - Stable | (6.58) - (21.19) | (13.89) | -446.3% |
| DDM - Multi | (6.26) - (15.76) | (8.97) | -323.6% |
| Market Cap (mil) | 294.05 |
| Beta | 1.88 |
| Outstanding shares (mil) | 73.33 |
| Enterprise Value (mil) | 292.67 |
| Market risk premium | 4.60% |
| Cost of Equity | 9.70% |
| Cost of Debt | 5.00% |
| WACC | 6.68% |